Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions: ANG003 Dose A, ANG003 Dose B, Creon; Drug
Lead sponsor: Anagram Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 24 more

Conditions: Autism Spectrum Disorder
Interventions: NDBI; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 1 Year and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD)
Interventions: Zeleciment Rostudirsen (DYNE-251), Placebo; Drug
Lead sponsor: Dyne Therapeutics; Industry
Eligibility: 4 Years to 18 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Hillsborough, North Carolina

Conditions: Tobacco Cessation, Tobacco Abstinence, Tobacco Use, Tobacco Use Cessation, Tobacco Dependence
Interventions: Nicotine Replacement Therapy (NRT), Wellness Coaching; Drug · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions: BL-M07D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more

Conditions: Malignant Peripheral Nerve Sheath Tumors
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2053
U.S. locations: 9
States / cities: Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more

Conditions: AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8, Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8, Plasmablastic Lymphoma, Primary Effusion Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Glofitamab, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Interventions: transcranial direct current stimulation, Sham stimulation; Device
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: CPPD - Calcium Pyrophosphate Deposition Disease
Interventions: Colchicine Pill, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 1 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Taletrectinib, Placebo; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more

Conditions: Chronic Low-back Pain
Interventions: Deep Brain Stimulation of the Subgenus Cingulate Cortex; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Dallas, Texas

Conditions: Age-Related Macular Degeneration
Interventions: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin; Drug
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Lung Transplant; Complications
Interventions: Tacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Traumatic Brain Injury
Interventions: Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention; Diagnostic Test
Lead sponsor: Samuel Cramer; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hearing Handicap
Interventions: STM Training, Speech Training, Mixed Training, Gamified Training, Foraging Training; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Riverside, California • Boston, Massachusetts • Portland, Oregon

Conditions: Alzheimer Disease, Family Members
Interventions: GENUS; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Central Nervous System Lymphoma
Interventions: Aspiration, Biospecimen Collection, Catheterization, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: AF - Atrial Fibrillation
Interventions: Pulse Field Ablation; Procedure
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Leiomyoma, Uterine, Leiomyoma, Fibroid, Fibroid Uterus
Interventions: Letrozole 2.5mg, Placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 53 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more

Conditions: Acute Myeloid Leukemia (AML) in Remission
Interventions: CPX-351; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey • Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer, Adult, Prehabilitation
Interventions: Multimodal Prehabilitation; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Worester, Massachusetts

Conditions: Serious Mental Illness, Older Adults
Interventions: Hopeful and Healthy Living (HHL); Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Head Cancer, Neck Cancer, Sarcopenia, Head and Neck Cancer
Interventions: exercise and nutritional prehabilitation; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Sacramento, California

Conditions: Hypertension, High Blood Pressure
Interventions: BPCARE Intervention; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: San Diego, California

Search by objective public record fields.

Phase 2 Study to Assess the Safety and Efficacy of ANG003

Improving Barriers to Care Access for Children With Autism and Related Needs Via Telehealth for Evaluation, Care Navigating, and Caregiver Coaching

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")

Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways

Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

DBS of the SCC for the Treatment of Medically Refractory CLBP

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Cortical Spreading Depolarization After Severe Traumatic Brain Injury

Mediators and Moderators of Auditory Training

Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

Comparison of Two Pulse Field Ablation Systems for AF Ablation

Prescription of Letrozole for Uterine Myoma

Phase IB/II of CPX-351 for Relapse Prevention in AML

Prehab for Pancreatic Cancer Surgery

A Pilot Randomized Controlled Trial of the Hopeful and Healthy Living Program

Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients

Blood Pressure Care for Advancing Real-World Evidence (BPCARE)